NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT01951469,Gefitinib With or Without Chemotherapy in Brain Metastases From Non-small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT01951469,,UNKNOWN,"This is a multi-center phase III randomized controlled study to assess the efficacy of Gefitinib alone and Gefitinib combination with Pemetrexed/platinum on patients with brain metastasis from non-small cell lung cancer(NSCLC) harboring EGFR mutation type by intracranial PFS(iPFS),also PFS ,DCR and OS.The side effect is evaluated as well.",NO,Non-small Cell Lung Cancer|Brain Metastases|EGFR Mutation,DRUG: Gefitinib and Pemetrexed/platinum|DRUG: Gefitinib mono-therapy,"iPFS(intracranial progression free survival, defined as time from randomization to intracranial progressive disease or death., 2 years","ORR, proportion of patients with complete or partial response of overall lesions, 2 years|intracranial objective response rate (iORR), proportion of patients with complete or partial response of intracranial lesions, 2 years|PFS(Progression Free Survival), time from randomization to overall disease progression or death, 2 years|OS(Overall Survival), time from randomization to death from any cause, 3 years|adverse events, adverse events were evaluated according to NCI-CTCAE 4.0., 3 years",,Sun Yat-sen University,Wu Jieping Medical Foundation,ALL,"ADULT, OLDER_ADULT",PHASE3,160,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,NSCLC brain metastasis 01,2016-01,2022-06,2022-12,2013-09-26,,2022-03-08,"Sun Yat-sen University of Cancer Center, Guangzhou, Guangdong, 510060, China",
